This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* Percutaneous Coronary Intervention for Cardiogenic Shock: Lessons and Advances
* Case Presentation
* Percutaneous Coronary Intervention for Cardiogenic Shock: Lessons and Advances
* CS in 2006: New Lessons
* Incidence of CS: Constant
* Why Haven t We Reduced Incidence of CS?
* Constant CS: Creating High-risk Situations
* Is CS Iatrogenic? COMMIT STEMI Trial
* CS Mortality: Still High After SHOCK?
* CS: Good News 87% of 1-yr Survivors Are NYHA I/II
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest, Harold Dauerman, MD, serves as a consultant for Arginox Pharmaceuticals. Dr.
Dauerman also receives research grants from or is an advisory board member for Arginox,
Genentech, Boston Scientific, and Guidant.
|
|